http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CA-2247191-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1374dd16777534b65ad4422333245af8 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0043 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-14 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00 |
| filingDate | 1997-02-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9674430cbc5b310b6176f13696812d00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d6278b188188e1647b81bad60248e45c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_88d48bb034a2ca3c803f6b7f5533ccb7 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_49d3fa0c1fcc541ffa90e6d785c01605 |
| publicationDate | 1997-09-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CA-2247191-A1 |
| titleOfInvention | Powdery composition for nasal administration |
| abstract | The present invention relates to a powdery composition for nasal administration, which is characterized in that (1) the composition contains (i) a drug, (ii) a water-absorbing and gel-forming base material such as hydroxypropyl cellulose or hydroxypropylmethyl cellulose and (iii) a water-absorbing and water-insoluble base material such as crystalline cellulose or .alpha. -cellulose, (2) wherein the amount of the water-absorbing and gel-forming base material is about 5-40 wt % based on the total of the water-absorbing and gel-forming base material and the water-absorbing and water-insoluble base material, and (3) wherein the drug is unevenly dispersed more on/in the water-absorbing and water-insoluble base material than on/in the water-absorbing and gel-forming base material. The present invention provides the powdery composition for nasal administration excellent in absorption of the drug from the nasal cavity and having an extremely increased maximum blood concentration comparing a conventional composition for nasal administration even for a drug having a high solubility in water, a drug having a high lipophilicity or a peptide/proteinaceous drug having a large molecular weight. |
| priorityDate | 1996-02-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 22.